Patents by Inventor Marina Savelieva Praz

Marina Savelieva Praz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20240150485
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS).
    Type: Application
    Filed: June 8, 2023
    Publication date: May 9, 2024
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20220081488
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Application
    Filed: October 6, 2021
    Publication date: March 17, 2022
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Regimens and methods of treating multiple sclerosis using ofatumumab
    Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20190177424
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 13, 2019
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn